Nasdaq Confirms TransCode Therapeutics' Compliance with Listing Rules

13 June 2024

BOSTON, June 10, 2024 - TransCode Therapeutics (Nasdaq: RNAZ), an RNA-focused oncology firm, has confirmed its continued compliance with Nasdaq listing standards. Consequently, the company's shares will remain listed on the Nasdaq Stock Market. This announcement follows a notification from Nasdaq indicating that TransCode has met all required listing criteria.

TransCode had previously been scheduled for a hearing before the Nasdaq Hearing Panel on June 25, 2024. However, this hearing has been canceled due to the company's restored compliance. Despite this, TransCode will still be under mandatory monitoring by a Nasdaq panel until January 26, 2025.

TransCode's Interim CEO and CFO, Tom Fitzgerald, expressed optimism about the company's future. He highlighted recent achievements, including positive blood test results from a Phase 0 clinical trial and FDA approval to proceed with a Phase 1 study. Fitzgerald emphasized that TransCode is well-positioned to advance its clinical programs rapidly. With the company's share price now above Nasdaq's $1.00 minimum bid price, there are no current plans for a reverse stock split.

About TransCode Therapeutics

TransCode Therapeutics is a clinical-stage oncology firm dedicated to treating metastatic diseases through RNA therapeutics. The company utilizes its proprietary TTX nanoparticle platform for the intelligent design and delivery of these treatments. Their leading candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker closely linked with metastasis. The company's broader portfolio aims to address the challenges of RNA delivery, potentially unlocking new genetic targets relevant to various cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!